PCVX Q2 2023 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$87M

Net Income

-$68M

EPS (Diluted)

$-0.70

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$61M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$69M

Stockholders' Equity

$1.4B

Cash & Equivalents

$531M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$87M	-$48M	-82.0%
Net Income	-$68M	-$49M	-40.8%